Article Per Year (5 Year)
p-Index From 2020 - 2025
0.562
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer Indonesian Journal of Cancer Pharmaceutical Sciences and Research (PSR) Jurnal Farmasi Indonesia
DENNI JOKO PURWANTO, DENNI JOKO
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 6 Documents
Search

 1 
Risiko Kanker Payudara pada Pengguna Obat-obatan Hormonal PURWANTO, DENNI JOKO; REUWPASSA, JAUHARI OKA; ADISASMITA, ASRI C
Indonesian Journal of Cancer Vol 8, No 2 (2014): April-Juni 2014
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Commonly hormonal drugs used by woman are contraceptive and hormone replacement therapy (HRT). A contraceptive user in Indonesia is about 62% aged 16-49 years, modern contraceptive users is 58%. Injected contraception user is 32% followed by oral contraceptive (pill) is 14%. Literature review conducted in this study. The risk use of both hormonal contraception and HRT causing breast cancer still have different opinion The researchers concluded that both of these factors affect the incidence of breast cancer.
Palliative Surgery in Breast Cancer PURWANTO, DENNI JOKO
Indonesian Journal of Cancer Vol 4, No 5 (2010): Workshops 2010
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

https://www.scribd.com/doc/43614373/Palliative-Surgery-in-Breast-Cancer
Preoperative Neoadjuvant Hormonal Therapy and Neoadjuvant Chemotherapy for Stage 3B and 4 Breast Cancer Patients in Dharmais Hospital-National Cancer Center, Indonesia: A Cohort Study Karsono, Ramadhan; Purwanto, Denni Joko; Haryono, Samuel J.; Karsono, Bambang; Sari, Lenny; Pratiwi, Yulia; Aryandono, Teguh
Indonesian Journal of Cancer Vol 12, No 4 (2018): October-December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (891.03 KB) | DOI: 10.33371/ijoc.v12i4.604

Abstract

Background: There are no data of efficacy comparison between primary systemic therapy in stage 3B and 4 breast cancer patients in Indonesia. This study compared long term outcomes of breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)Methods: This was a cohort study conducted from 2011 to 2017. A total of 122 patients with stage 3B and 4 breast cancer received NAHT (n = 62) or NACT (n = 60) within a 6 cycles for NACT and 6 months for NAHT were included. Patients were excluded if they had a mastectomy before treatment, were pregnant, had been given hormonal therapy or chemotherapy before, had a contra-indication of chemotherapy, had a contra-indication of salpingo-oophorectomy bilateral for premenopausal patients, and declined to enter this study. The primary outcome of this study was overall survival. The outcomes were analysed using Kaplan-Meier for survival analysis and cox proportional hazard regression to estimate the hazard ratio.Results: There was a statistically significant difference in overall survival (p = 0.038). Median overall survival for NAHT patients was 1265 days and for NACT patients was 654 days. The hazard ratio showed NACT patients had a higher risk than NAHT patients (1.7 95% CI 1.03 – 2.9). Pathological complete response rate was higher in the NACT group than in the NAHT group (3.3% vs. 0%).Conclusions: Neoadjuvant hormonal therapy was superior to neoadjuvant chemotherapy in term of overall survival.
Profiles of Cancer Patients at Surgical Oncology Outpatient Clinic at Dharmais Cancer Hospital as National Referral Hospital in Indonesia from 2017 to 2021 Sofyan, Rian Fabian; Ramadhan, Ramadhan; Purwanto, Denni Joko; Gautama, Walta; Dien, Alban W; Brahma, Bayu; Iskandar, Bob Andinata; Kurniawan, Febriyanto; Husein, Abdul Muhaimin; Sabatini, Nafilla Nesantya; Ginawang, Asto
Indonesian Journal of Cancer Vol 18, No 2 (2024): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i2.1090

Abstract

Background: Cancer is one of the leading causes of death in the world. Dharmais Cancer Hospital is set to be the National Cancer Center with an obligation to support all hospitals throughout the country that specialize in cancer. Surgical Oncology is one of the departments that handles the most cases in Dharmais Cancer Hospital. The types of cancers that are managed in Surgical Oncology Departments are breast cancer, head and neck cancer, thyroid cancer, skin cancer, and soft tissue cancer. Objective: This paper aims to find the newly diagnosed cancer patients’ characteristics and socioeconomic features in Dharmais National Cancer Center from 2017 to 2021. Methods: The study was a cross-sectional descriptive study using the medical record database of outpatients at Dharmais Cancer Hospital as a data collection method from 2017 until 2021. The sample size includes all new cancer patients in Dharmais Cancer Hospital that have been recorded. Result: Over 500,000 patients visited Dharmais Cancer Hospital in the last 5 years with an average of over 100,000 visits per year. Over 90% of the patients have solid tumors, and over eight thousand patients were admitted to the Surgical Oncology Outpatient Clinic, it was concluded that the most frequently diagnosed type of cancer is breast cancer (66.7%) of all types of cancer in the past 5 years. Most of the new patients are female (88.1%) with the most common age group of 40 to 55 years old (50.7%). Most of the patients are senior high school graduates (42.8%). Conclusions: The general characteristic of cancer patients is dominated by breast cancer patients, most patients are female, in the age group between 40 to 55 years old, and senior high school graduates. Further studies need to be done on each type of cancer to have a better understanding of the profiles and characteristics of solid cancer patients in Dharmais Cancer Hospital. 
Reaksi Merugikan Obat Kanker Berbasis Antrasiklin pada Pasien Kanker Payudara di RS Kanker Dharmais Chairunnisa, Dian Fitri; Harahap, Yahdiana; Syafhan, Nadia Farhanah; Purwanto, Denni Joko
JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X Vol. 16 No. 1 (2024): Jurnal Farmasi Indonesia
Publisher : Pengurus Pusat Ikatan Apoteker Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35617/jfionline.v16i1.164

Abstract

Breast cancer is the type of cancer that most often affects women worldwide. Doxorubicin is an anthracycline class, a first-line anticancer therapy with clinical activity in breast cancer. Doxorubicin can cause cardiotoxic effects due to the formation of doxorubicinol as its primary metabolite. Adverse drug reactions also vary depending on the chemotherapy regimen. This study aimed to determine the adverse reactions to anthracycline-based drugs that breast cancer patients often experience. This observational descriptive study was conducted from April to July 2022 at the Dharmais Cancer Hospital, Jakarta. The sample in this study was breast cancer patients undergoing chemotherapy with anthracycline-based regimens. Data were collected through interviews and observation of medical records, which were analyzed by univariate analysis. The results showed that the most frequent drug reaction was alopecia, with a percentage of 97.1%. They were followed by nausea at 85.7%, vomiting at 71.4% and pain at 65.7%. The fastest time for nausea to appear is within 18-24 hours (peak days 2 to 3) after chemotherapy. Did not experience a decrease in left ventricular ejection fraction by 34.3%, and 65.7% experienced a reduction in left ventricular ejection fraction after doxorubicin chemotherapy. Patients who underwent a reduction in left ventricular ejection fraction after doxorubicin chemotherapy had a decrease in ejection fraction <10%, and no patients experienced a decline in left ventricular ejection fraction >10%. Breast cancer patients who receive anthracycline-based treatment can experience adverse drug reactions, including nausea, vomiting, alopecia, pain and decreased left ventricular ejection fraction.
Recent Updates on Dried Blood Spot and Volumetric Absorptive Microsampling as Microsampling Technique for Antiepileptic Drug Determination: A Systematic Review Pridilla, Asmiladita; Harahap, Yahdiana; Purwanto, Denni Joko; Maggadani, Baitha Palanggatan
Pharmaceutical Sciences and Research
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Implementation of Therapeutic Drug Monitoring (TDM) can be useful for patients with uncontrolled seizures. This review article aims to collect and compare the recent development of bioanalytical methods for antiepileptic drugs using microsampling techniques, namely DBS (Dried Blood Spot) and VAMS (Volumetric Absorptive Microsampling). Studies were searched through databases, namely Science Direct, Pubmed, and the Google Scholar search engine using pre-determined keywords. Studies published between 2019 and 2024 and used micro-sampling techniques for antiepileptic drug analysis were included. Non-English studies, non-related studies, duplication, and full text unavailable were excluded. Primary sources were used to build a conclusion regarding the purpose of this review article. A total of 342 articles were identified from databases. From 8 primary studies included, analytical methods for 21 drug compounds as antiepileptic agents and 4 of their metabolites in DBS and VAMS were found. A summary of sample preparation, analytical method, and validation were presented in the narrative form of this review. Concentrations measured using DBS and VAMS demonstrate a strong correlation with conventional matrices; however, conversion factors based on the blood-to-plasma ratio are necessary for accurate comparison. Additionally, the comparison results between DBS and VAMS technique for TDM is still unsatisfactory to prove their interchangeability. Therefore, this comparison needs further evaluation with more samples and more analytes. Analysis of antiepileptic drugs using VAMS is also still limited and further optimization can be carried out to produce more stable, sensitive, fast, and suitable for TDM practice.
Co-Authors Asri C. Adisasmita Baitha Palanggatan Maggadani, Baitha Palanggatan Bambang Karsono Brahma, Bayu Chairunnisa, Dian Fitri Dien, Alban W Gautama, Walta Ginawang, Asto Haryono, Samuel J. Husein, Abdul Muhaimin Iskandar, Bob Andinata JAUHARI OKA REUWPASSA, JAUHARI OKA Karsono, Ramadhan Kurniawan, Febriyanto Lenny Sari, Lenny Nadia Farhanah Syafhan Pridilla, Asmiladita Ramadhan Ramadhan Sabatini, Nafilla Nesantya Sofyan, Rian Fabian Teguh Aryandono Yahdiana Harahap Yulia Pratiwi